Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where William S. Helton is active.

Publication


Featured researches published by William S. Helton.


American Journal of Surgery | 2013

Repair of incisional hernias with biological prosthesis: a systematic review of current evidence

Charles F. Bellows; Alison Smith; Jennifer Malsbury; William S. Helton

BACKGROUND No consensus has been reached on the use of bioprosthetics to repair abdominal wall defects. The purpose of this systematic review was to summarize the outcomes from studies describing this use of various bioprosthetics for incisional hernia repair. METHODS Studies published by October 2011 were identified through literature searches using EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials. RESULTS A total of 491 articles were scanned, 60 met eligibility criteria. Most studies were retrospective case studies. The studies ranged considerably in methodologic quality, with a modified Methodological Index of Nonrandomized Studies score from 5 to 12. Many repairs were performed in contaminated surgical sites (47.9%). At least one complication was seen in 87% of repairs. Major complications noted were wound infections (16.9%) and seroma (12.0%). With a mean follow-up period of 13.6 months the hernia recurrence rate was 15.2%. CONCLUSIONS There is an insufficient level of high-quality evidence in the literature on the value of bioprosthetics for incisional hernia repair. Randomized controlled trials that use standardized reporting comparing bioprosthetics with synthetic mesh for incisional hernia repair are needed.


Annals of Surgery | 2016

Interferon-based adjuvant chemoradiation for resected pancreatic head cancer long-term follow-up of the Virginia mason protocol

Flavio G. Rocha; Yasushi Hashimoto; Traverso Lw; Russell Dorer; Richard A. Kozarek; William S. Helton; Vincent J. Picozzi

Objective:To report the long-term impact of adjuvant interferon-based chemoradiation therapy (IFN-CRT) after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PDAC). Background:In 2003, we reported an actuarial 5-year overall survival (OS) of 55% (22 months median follow-up) using adjuvant IFN-CRT after PD. As the original cohort is now 10 years distant from PD, we sought to examine their actual survival, describe patterns of recurrence, and determine prognostic factors. Methods:From 1995 to 2002, 43 patients underwent PD for PDAC and received adjuvant IFN-CRT consisting of external-beam irradiation, continuous 5-fluorouracil infusion, weekly intravenous bolus cisplatin, and subcutaneous interferon-&agr;. Survival was calculated by the method of Kaplan and Meier, and prognostic factors were compared using a log-rank test and a Cox proportional hazards model. Results:With all patients at least 10 years from PD, the 5-year actual survival was 42% and 10-year actual survival was 28% with median OS of 42 months (95% confidence interval: 22–110 months). Nine patients survived beyond 10 years with 7 currently alive without evidence of disease. Initial recurrence included 4 local, 17 distant, and 4 combined sites at a median of 25 months. IFN-CRT was interrupted in 70% of patients because of grade 3 or 4 toxicity, whereas 42% of patients required hospitalization. Adverse prognostic factors included lymph node ratio of 50% or more, Eastern Cooperative Oncology Group performance status of 1 or higher, and IFN-CRT treatment interruption. Conclusions:Adjuvant IFN-CRT after PD can provide long-term survival in resected PDAC. Further studies should focus on patient and tumor factors to maximize benefit and minimize toxicity.


Hpb | 2016

Classification and techniques of en bloc venous reconstruction for pancreaticoduodenectomy

Farzad Alemi; Flavio G. Rocha; William S. Helton; Thomas Biehl; Adnan Alseidi

BACKGROUND Surgical resection is the only cure for hepato-pancreato-biliary (HPB) malignancy. In the era of multidisciplinary approaches and neoadjuvant therapies for locally advanced, borderline resectable tumors, the feasibility and efficacy of en bloc vascular resection has been validated across multiple studies. However, the variability of venous anatomy within the perihepatic and peri-portal regions necessitates familiarity with alternative resection and reconstruction techniques appropriate to the specific region of tumor invasion. METHODS To organize these paradigms, the venous system has been divided into five zones: 1) hepatic hilum; 2) hepatoduodenal ligament; 3) portal vein/splenic vein confluence, which is further subdivided into right (3a) and left (3b); 4) infra-confluence; and 5) splenic vein. RESULTS This study systematically analyzes the anatomic considerations and clinical scenarios specific to each zone to organize the necessary preparative maneuvers, surgical procedures, and vascular reconstruction techniques to achieve an R0 resection. The anatomic and tumor-specific factors which deem a specimen unresectable are also explored. Surgical videos demonstrating these techniques are presented. DISCUSSION Preparation and familiarity with venous reconstruction maneuvers is essential for an oncologically effective operation, and can be safely achieved by utilizing this logical anatomic and procedural framework.


Annals of Surgical Oncology | 2017

Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective

Vincent J. Picozzi; Stephen Y. Oh; Alicia Edwards; Margaret T. Mandelson; Russell Dorer; Flavio G. Rocha; Adnan Alseidi; Thomas Biehl; L. William Traverso; William S. Helton; Richard A. Kozarek


Hpb | 2016

What is a better predictor of clinically relevant postoperative pancreatic fistula (CR-POPF) following pancreaticoduodenectomy (PD): postoperative day one drain amylase (POD1DA) or the fistula risk score (FRS)?

Kimberly Bertens; Angelena Crown; Jesse Clanton; Farzad Alemi; Adnan Alseidi; Thomas Biehl; William S. Helton; Flavio G. Rocha


Journal of Clinical Oncology | 2017

Gemcitabine/taxane adjuvant therapy in resected pancreatic cancer: A signal of improved survival?

Zaheer S. Kanji; Alicia Edwards; Margaret T. Mandelson; Bruce S. Lin; K. Badiozamani; Goubin Song; Adnan Alseidi; Thomas Biehl; Richard A. Kozarek; William S. Helton; Vincent J. Picozzi; Flavio G. Rocha


Hpb | 2018

Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma

Jesse Clanton; Stephen Y. Oh; Stephen J. Kaplan; Emily Johnson; Andrew S. Ross; Richard A. Kozarek; Adnan Alseidi; Thomas Biehl; Vincent J. Picozzi; William S. Helton; David L. Coy; Russell Dorer; Flavio G. Rocha


Annals of Surgical Oncology | 2018

Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?

Zaheer S. Kanji; Alicia Edwards; Margaret T. Mandelson; Nadav Sahar; Bruce S. Lin; K. Badiozamani; G. Song; Adnan Alseidi; Thomas Biehl; Richard A. Kozarek; William S. Helton; Vincent J. Picozzi; Flavio G. Rocha


Journal of Clinical Oncology | 2017

Adjuvant therapy (AT) following resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?

Kimberly Bertens; John Massman; Samuel Garbus; Margaret T. Mandelson; Bruce S. Lin; Vincent J. Picozzi; Adnan Alseidi; Thomas Biehl; William S. Helton; Flavio G. Rocha


Hpb | 2017

Demonstration of a Hepp-Couinaud roux-en-y hepaticojejunostomy for an E3 biliary injury

S. Deal; Adnan Alseidi; Flavio G. Rocha; Thomas Biehl; William S. Helton

Collaboration


Dive into the William S. Helton's collaboration.

Top Co-Authors

Avatar

Flavio G. Rocha

Virginia Mason Medical Center

View shared research outputs
Top Co-Authors

Avatar

Adnan Alseidi

Virginia Mason Medical Center

View shared research outputs
Top Co-Authors

Avatar

Thomas Biehl

Virginia Mason Medical Center

View shared research outputs
Top Co-Authors

Avatar

Vincent J. Picozzi

Virginia Mason Medical Center

View shared research outputs
Top Co-Authors

Avatar

Richard A. Kozarek

Virginia Mason Medical Center

View shared research outputs
Top Co-Authors

Avatar

Margaret T. Mandelson

Virginia Mason Medical Center

View shared research outputs
Top Co-Authors

Avatar

Alicia Edwards

Virginia Mason Medical Center

View shared research outputs
Top Co-Authors

Avatar

Bruce S. Lin

Virginia Mason Medical Center

View shared research outputs
Top Co-Authors

Avatar

Farzad Alemi

University of Missouri–Kansas City

View shared research outputs
Top Co-Authors

Avatar

Jesse Clanton

Virginia Mason Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge